This week’s newsletter covers the latest research and journalism on plant medicine, including a landmark study on psilocybin microdosing and creativity, debates over non-hallucinogenic psychedelics, neuroplasticity and addiction treatment, quality control in the psychedelic products market, and psilocybin’s potential for chronic pain relief.
Noteworthy Read
Major New Study Finds Psilocybin Microdoses Improve the Quality of Creative Ideas But Not the Quantity (Psypost)
Psychedelics have often been described anecdotally as substances that lead to enhanced creativity. Recently, a large study reported that people who microdose psilocybin generated higher-quality creative ideas (more original and useful), but did not produce a greater number of ideas.
Read the articleView more in Psychedelics
More Noteworthy Reading
Sanitizing Psychedelics: The Biopolitics of Non-Hallucinogenic Psychoplastogens (Springer)
This article argues that emerging “non-hallucinogenic psychoplastogens” — compounds designed to trigger neuroplasticity without subjective psychedelic effects — challenge core assumptions about psychedelic therapy by reframing healing as purely biological and bypassing experiential transformation, raising questions about the future of these substances mental health treatment.
Read moreView more in Psychedelics
Could Psychedelics Harness Neuroplasticity to Treat Addiction and Mental Illness? (NIDA)
The National Institute on Drug Abuse explores how psychedelics might promote neuroplasticity — the brain’s ability to adapt and reorganize — to help treat addiction and other mental health disorders, though research is ongoing and human trials are limited.
Read moreView more in Psychedelics
The Fight for Psychedelic Product Integrity (Lucid News)
Industry stakeholders are pushing for stronger quality control, testing standards, and transparency in the rapidly expanding psychedelic products market to protect consumers and build trust amid concerns about contamination, mislabeling, and unverified formulations.
Read moreView more in Psychedelics
Research Round-Up
Psilocybin and Chronic Pain (MDPI)
A Diseases (MDPI) review article explores evidence that psilocybin may modulate pain perception and reduce chronic pain via neuroplastic and emotional processing pathways, highlighting mechanisms, clinical findings, and gaps that warrant further human research.
Read moreView more in Psychedelics
A heartfelt thank you to all of the CBD brands whose generous support makes it possible for Project CBD to shine a light on the most important emerging research in plant medicine — your partnership truly matters.
Be the first to comment